Head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic CRPC
The approval of enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) provided an important life-extending drug. Now the sequencing and uses of enzalutamide are bei...
Author: VJOncology
Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts
New Data Change Metastatic Prostate Cancer Treatment Paradigm
Dr Chodak reviews results of the LATITUDE trial, which compared ADT alone versus ADT with abiraterone acetate plus prednisone. (Source: Medscape Urology Podcast)
Source: Medscape Urology Podcast - August 14, 2017 Category: Urology & Nephrology Authors: Medscape Source Type: podcasts
How do you choose between or identify the right patient for Zytiga or Xtandi?
Nicholas J. Vogelzang, MD of Comprehensive Cancer Centers of Nevada explains how he chooses the right prostate cancer patient for Zytiga (abiraterone acetate) or Xtandi (enzalutamide) at the 2017 ASCO...
Author: obr
Added: 06/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 23, 2017 Category: Cancer & Oncology Source Type: podcasts
Identifying the right patient for Zytiga (Abiraterone) or Xtandi (Enzalutamide)
Christopher J. Logothetis, MD of MD Anderson Cancer Center discusses how he identifies and chooses the right patients for abiraterone and enzalutamide at the 2017 ASCO Annual Meeting in Chicago, IL.
Author: obr
Added: 06/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2017 Category: Cancer & Oncology Source Type: podcasts
Overview of STAMPEDE Study
Nancy Dawson, MD of Lombardi Cancer Center at Georgetown University Hospital gives an overview of the STAMPEDE study, which focuses on the use of abiraterone acetate in the treatment of prostate cance...
Author: obr
Added: 06/20/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 20, 2017 Category: Cancer & Oncology Source Type: podcasts
Trial of LHRHa, abiraterone and enzalutamide: filling an unmet need in prostate cancer therapy
Eleni Efstathiou, MD, PhD of the University of Texas MD Anderson Cancer Center, Houston, Texas, TX, provides an overview of the Phase II trial of leuprolide acetate (LHRHa) and abiraterone acetate wit...
Author: VJOncology
Added: 08/25/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 25, 2016 Category: Cancer & Oncology Source Type: podcasts
IMAAGEN: Phase 2 trial of abiraterone acetate plus prednisone for advanced prostate cancer | Dr Neal Shore at ASCO 2015
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, provides an update on IMAAGEN, a multicentre, open-label, ...
Author: EMJ
Added: 08/26/2015 (Source: Oncology Tube)
Source: Oncology Tube - August 26, 2015 Category: Cancer & Oncology Source Type: podcasts
Neoadjuvant abiraterone acetate plus leuprolide acetate in localised high-risk prostate cancer | Dr Eleni Efstathiou at ASCO 2015
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a study ...
Author: EMJ
Added: 07/16/2015 (Source: Oncology Tube)
Source: Oncology Tube - July 16, 2015 Category: Cancer & Oncology Source Type: podcasts
Dr. Scholz discusses the use of Abiraterone in mCRPC
Dr. Scholz discusses the final analysis of the COU-AA-302 study, which compared abiraterone acetate to prednisone alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Mark ...
Author: onclivetv
Added: 03/04/2015 (Source: Oncology Tube)
Source: Oncology Tube - March 4, 2015 Category: Cancer & Oncology Source Type: podcasts
